viewGenedrive PLC

Additional Listing

/**/ link{ color: blue }visited{ color: #954F72 } .ao{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ao{}p.bq{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align: center}span.br{font-weight: bold}p.bs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bt{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.bu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bv{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.bx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify} span.bi{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.by{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:-9.0pt;margin-bottom:.0001pt;text-align:justify}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.be{font-size:12.0pt;font-family:"Times New Roman","serif"}table.ca{width:459.0pt;margin-left:-10.15pt;border-collapse:collapse}td.bc{width:251.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}td.az{width:185.95pt;padding:0cm 5.4pt 0cm 5.4pt}p.cc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}span.bb{font-size:9.0pt;color:windowtext} span.ay{font-size:12.0pt; font-family:"Times New Roman","serif"}tr.av{height:5.65pt}td.ax{width:251.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:5.65pt}td.aw{width:185.95pt;padding:0cm 5.4pt 0cm 5.4pt; height:5.65pt}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -19.25pt; margin-top: 0cm}span.at{font-size:9.0pt; color:windowtext}td.as{width:232.2pt;padding:0cm 5.4pt 0cm 5.4pt}td.ar{width:205.2pt;padding:0cm 5.4pt 0cm 5.4pt}td.aq{border:none}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} /**/
RNS Number : 8425V
Genedrive PLC
05 December 2019

genedrive plc

("genedrive" or the "Company")


 Additional listing


genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that, further to the announcement of the fifth deed of amendment to the Visible Genomics SPA on 16 November 2018, it has issued 869,565 ordinary shares of 1.5p each in the capital of the Company ("VGL Shares") to the shareholder of Visible Genomics Limited. This is to settle the deferred consideration payable on the first anniversary of the date of admission of the shares issued in the placing on which the amendment was conditional. The VGL Shares will be subject to an orderly marketing arrangement.


Application has been made to the London Stock Exchange for the VGL Shares to be admitted to trading on AIM. Admission is expected to be effective on 10 December 2019. The VGL Shares shall rank pari passu with the existing ordinary shares in the Company.


Following admission, the Company's issued share capital will comprise 34,870,071 Ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 34,870,071. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.


For further details please contact:


genedrive plc


David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245

Peel Hunt LLP

+44 (0)20 7418 8900

James Steel / Oliver Jackson

Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001


Notes to Editors


About genedrive plc


genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Genedrive PLC

Price: 21.5

Market: AIM
Market Cap: £7.5 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: Genedrive reports 'high clinical accuracy' for its AIHL...

Headlines from Proactive UK newsroom. Genedrive (LON:GDR) has scored 100% diagnostic sensitivity and 100% specificity in a test of its assay kit to identify babies at risk of hearing loss from the use of antibiotic gentamicin. The clinical study was based on 303 samples. Gold miner...

on 3/12/19